| TAH Drug Code | EPROS |
|---|---|
| Indications | Induction & augmentation of labor near term. |
| Dosing | Initially, insert 1 vaginal tablet high into posterior fornix. Second tablet may be inserted after 6-8 hr if labor is not established. the maximum dose: 6 mg in 24 hr. |
| Hepatic Impairment | Dose adjustment not necessary |
| Renal Impairment | Dose adjustment not necessary |
| Contraindications | Hypersensitivity to Prostin E2 (dinoprostone), prostaglandins, or any other component of the product. Do not use in patients in whom oxytocic drugs are generally contraindicated such as: - multiple gestation - grand multiparity (6 or more previous term pregnancies) - engagement of the head has not taken place - previous uterine surgery (e.g., cesarean section, hysterotomy) - cephalopelvic disproportion - fetal heart rate pattern suggests incipient fetal compromise - obstetric conditions where either maternal or fetal benefit/risk ratio favors surgical intervention - unexplained vaginal discharge and/or abnormal uterine bleeding during current pregnancy - nonvertex presentation |
| Adverse Effects | Common: Diarrhea (Vaginal insert, <1%; vaginal suppository, approximately 40%), Nausea (Vaginal insert, <1%; vaginal suppository, 33%), Vomiting (Vaginal insert, <1%; vaginal suppository, approximately 66%), Headache (Vaginal suppository, approximately 10%), Fever (vaginal insert, <1%), Shivering (Vaginal suppository, approximately 10%) Serious: Decreased diastolic arterial pressure (Vaginal suppository, 10%), Myocardial infarction, Disseminated intravascular coagulation, Hypersensitivity reaction, Hypertonic uterine dysfunction (Vaginal insert, 2-4.7%), Infection of amniotic cavity, Intrauterine sepsis of fetus, Non-allergic anaphylaxis, Premature rupture of membranes, Rupture of uterus, Vaginospasmm, Fetal distress (Vaginal insert, 2.9-3.8%) |
| Pregnancy | Contraindicated |
| Lactation | No (Limited) Human Data - Probably Compatible |
| More Info | UpToDate |